A phase I trial of the intravenous Hsp90 inhibitor alvespimycin (17-DMAG) in patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.

ABSTRACT:

SUBMITTER: Maddocks K 

PROVIDER: S-EPMC5455147 | biostudies-literature | 2016 Sep

REPOSITORIES: biostudies-literature